Johnson Pharma is now a leading company that offers diversified pharmaceutical manufacturers and acts as a solution provider to healthcare issues. In this article, Johnson Pharma’s business model and its financial statements are reviewed, and Johnson Pharma Share Price Target from 2024 to 2050 have also been determined.
Currently, there is a growing number of investors’ attention to the healthcare industry. Johnson Pharma with an ideal background resulting from its sound foundation, more investment in R&D, and stable market position. We will also review factors affecting its stock price, and its prospects, and frequently asked questions.
About The Johnson Company
Johnson Pharma is one of the reputed pharma companies that deals in multiple segments such as generic & branded formulations & biotech products segment. The company’s operation mission is to provide quality medical care to everyone. As a result of strong research and development centers and the company’s mission to meet human health care requisites,
johnson pharma share price target has expanded its operations at the domestic as well as international levels. The list of the company’s specialties is represented with cardiovascular treatments, oncology drugs, diabetic care, and more, which is why it is a preferred partner for the improvement of global health.
What will be the Business Overview for Johnson Pharma India?
Johnson Pharma’s operations in India are strategically significant for the company’s global business plan to establish the firm as an essential stakeholder in one of the world’s biggest healthcare industries. Johnson Pharma focuses on the affordability of drug products in India while policy support from the distribution wing of the company along with special tie-ups with hospitals, clinics, and retail pharmacies.
The Indian segment also enjoys some government policies and has the scope to expand up with the help of new products, which will strengthen the position of Johnson Pharma more and more.
Key Fundamentals of Johnson Pharma
Due to this, investors have been showing a lot of interest in Johnson Pharma because of its good credentials. Some of the essential metrics include:
- Market Capitalization: It has good investor confidence and good valuation.
- P/E Ratio: In relation to earnings it symbolizes its value; currently reasonably they made up at the industry average for a good buy.
- Debt-to-Equity Ratio: The amount of debt-equity ratio is kept low as an indication of sound financial health of the company.
- Return on Equity (ROE): Suggests that earnings must be higher than several industry standards, to create rich returns for shareholders.
Market Cap | ₹ 58.3 Cr. |
Enterprise Value | ₹ 61.90 Cr |
52 Week High/Low | Rs. 1.44 and Rs. 0.51 |
Stock P/E | 27.94 |
Book Value | ₹1.03 |
Dividend Yield | 0.00 |
ROCE | -0.34 % |
ROE | -0.35 % |
Face Value | ₹ 1.00 |
Price to Book Value | 1.04 |
EPS | ₹0.00 |
Debt | ₹1.95 Cr |
Promoters Holding | 0% |
What will be the Financial Performance of Johnson Pharma?
The financial strength in Johnson Pharma’s revenue growth also adds value, stability, and fifteen solidity in that regard. Recent quarterly and annual reports highlight:
- Revenue Growth: The annual revenue has a gradual increase in product diversification and an increase in the demand for the products.
- Profit Margins: Enhanced levels of business revenues or increased sales growth owing to lower business costs on operations.
- R&D Expenditure: Sustaining with research and development expenditure, and improving its innovation capability and pipeline.
- Earnings per Share (EPS): Larger and higher EPS indicates improved operations and a healthier state of the business.
Revenue | $85.16 billion |
Net income | ₹0.19Cr |
Diluted EPS | 0.00 |
Net profit margin | -1.18% |
What will be the Share Holding Pattern for Johnson Pharma?
Understanding Johnson Pharma’s shareholding pattern can provide insight into its stability:
- Promoters: Significant major promoters still hold large stakes proving that they have faith in the future growth of the company.
- Institutional Investors: In this case, mutual funds and foreign institutional investors act well represented.
- Public Shareholders: A significant percentage is held by retail investors, suggesting that the markets are interested in and around liquid.
HOLDING | Sep 2024 | June 2024 |
Promoters Holding | 0% | 0% |
FII Holding | 0% | 0% |
DII Holding | 0% | 0% |
Public Holding | 100.0% | 100.0% |
Johnson Pharma Share Price Target 2024
Growth estimations based on the strategic introduction of new products and the expansion of sales within the domestic market is the target of 2024 that ranges between ₹1.07.
Year | Price Target |
2024 | ₹1.07 |
Johnson Pharma Share Price Target 2025
The market will also witness multiple sources of income and expansion of care in rural areas leading to growth. The Johnson Pharma Share Price Target 2025 is not available.
Year | Price Target |
2025 | Not available |
Johnson Pharma Share Price Target 2026
Higher growth potential through breaking into new international markets is making the market grow . But johnson pharma share price target of 2026 is not available.
Year | Price Target |
2026 | Not available |
Johnson Pharma Share Price Target 2027
The growth will be supported by escalating demand for new healthcare solutions. ₹5 is the johnson pharma share price target of 2027.
Year | Price Target |
2027 | ₹5 |
Johnson Pharma Share Price Target 2028
The Johnson Pharma share price target is not available but the Growth in distribution channels and improving brand equity in the Asia region can reach its heights.
Year | Price Target |
2028 | Not available |
Johnson Pharma Share Price Target 2029
In 2029 Revenue and profit improvement resulted from focused innovation and new partnerships sustained with the backing of research and development departments can happen. The exact target price of this year is not available
Year | Price Target |
2029 | not available |
Johnson Pharma Share Price Target 2030
A strong portfolio and increased market share are expected to aid this goa but the johnson pharma share price target is not available.
Year | Price Target |
2030 | not available |
Johnson Pharma Share Price Target 2035
Long-term objectives including the achievement and consolidation of the firm’s domination in the domestic and global markets can take place.
Year | Price Target |
2035 | not available |
Johnson Pharma Share Price Target 2040
The Johnson Pharma share price target in 2040 is not available.
Year | Price Target |
2040 | not available |
Johnson Pharma Share Price Target 2045
Healthcare growth to be led by preventive services; new opportunities for value creation cab happen in 2045. The johnson pharma share price target in 2045 is not available.
Year | Price Target |
2045 | not available |
Johnson Pharma Share Price Target 2050
An accumulation of factors such as capturing the market, providing innovations day in and day out, and operating internationally can happen in 2050. The Johnson Pharma share price target in 2050 may go high but exact information is not available.
Year | Price Target |
2050 | not available |
Factors Influencing Johnson Pharma Share Price Target
Below are the few factors influencing the Johnson Pharma share price target:
R&D Innovations: Cohesive innovation enables Johnson Pharma to remain relevant in the ever-changing health sector.
Regulatory Approvals: Accelerated time for approvals can affect the launch of new drugs, hence the consideration affects growth.
Market Competition: Other domestic and international competitors in the generic segment of cera maves might also have an impact on the price and demand.
Global Expansion: The revenue sources would be affected by the expansion into emerging markets.
Economic Conditions: Stability in the economic environment within the operational areas also influences growth rates as well as profitability.
What will be the Future Growth Prospects of the Johnson Pharma Company?
The strategic plan for Johnson Pharma includes the longevity of creating new products, expanding their market around the world, and creating new concentrations on therapeutic segments that need treatments such as cancer and heart diseases.
Further, such investment in the company offers rich prospects for future revenues through its investments in biotech and other preventive healthcare solutions. Being tomorrow’s emerging markets in Asia, Africa, and Latin America into strategic focus, Johnson Pharma is in a vantageous position to grow steadily in the next couple of decades.
Conclusion
Many investors seek long-term returns, and based on the detailed analysis of its operations and forecast figures for the next four years, Johnson Pharma can be the ideal investment for any investor. They have a stable financial position, a robust market that shows its dominance, and a wide product range making Johnson Pharma among the secure investments in the pharmaceutical industry.
The projected share price targets that have been set for the upcoming years also factor both the strengths and the opportunities of the firm’s growth firmly and reasonably.
FAQs
Johnson Pharma operates in cardiovascular, oncology, and diabetic care segments, biotechnology, and preventive medicine markets.
They are research and development innovation, competition, approvals, and economic factors.
The company has a good financial base, a global expansion plan, and consistent product development, which makes long-term investment safe and secure.
In the case of Johnson Pharma, the company adheres to an assertive R&D strategy to roll out new products at least once each year, and more so where the market sections are gaining a lot of attention.
Specifically, Johnson Pharma believes that there will be a continuous expansion where the company has focused its efforts, in Asia, Africa, and Latin America.
Disclaimer
This article is just for information and education purposes. These predictions and statistics of stock prices are just for educational purposes. We don’t recommend buying and selling any stocks of the company. Investors are responsible for conducting research on stock prices before investing in any stock. We are not responsible for loss and damage arising while using this stock price content.
